Justyna M. Przystal et al. proposed using a CSF1R inhibition antibody in single or combination therapy with a PD-1 antibody in a glioma mouse model and patient-derived micro-tumors (PDMs) [44]. Here, PDCD1 is linked to central nervous system cancer.